Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Authors

Florence Ader

Published

September 14, 2021

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Infectious Diseases

Topics

Randomized Controlled Trial

DOI

10.1016/s1473-3099(21)00485-0

License

publisher-specific-oa

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Authors

Florence Ader

Published

September 14, 2021

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Infectious Diseases

Topics

Randomized Controlled Trial

DOI

10.1016/s1473-3099(21)00485-0

License

publisher-specific-oa

Paper

Paper

Paper

Paper

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Abstract

Supporters

Journal

Topics

DOI

License

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Abstract

Supporters

Journal

Topics

DOI

License

Supporters

Journal

Topics

DOI

License